Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 3 |
Neoplasms | 2 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Synthetic peptide | 2 |
Hormone | 1 |
Drug conjugates | 1 |
Target |
Mechanism GR agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date25 Aug 2021 |
Target |
Mechanism NPRC agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date10 Dec 2024 |
Sponsor / Collaborator |
Start Date26 Jul 2024 |
Sponsor / Collaborator |
Start Date26 Jul 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Palopegteriparatide ( CaSR x PTH1R ) | Hypoparathyroidism More | Approved |
Lonapegsomatropin-tcgd ( GR ) | Growth hormone deficiency More | Approved |
Navepegritide ( NPRC ) | Achondroplasia More | NDA/BLA |
TransCon TLR7/8 Agonist(Ascendis Pharma) ( TLR7 x TLR8 ) | Locally Advanced Head and Neck Squamous Cell Carcinoma More | Phase 2 |
TransCon IL-2 beta/gamma(Ascendis Pharma) ( IL-2R ) | Advanced Head and Neck Squamous Cell Carcinoma More | Phase 2 |